Analytical Data
-
基因名
MIP-1 alpha/CCL3
- Application
-
别名
Macrophage inflammatory protein 1-alpha, Small-inducible cytokine A3
-
种属
Rat
-
表达系统
E. coli
-
标签
Tag Free
-
纯度
Greater than 98% as determined by SDS-PAGE.
-
蛋白编号
P50229
-
表达区间
24-92aa
-
蛋白长度
Partial
-
分子量
7.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIP-1 alpha, also known as CCL3 (chemokine (C-C motif) ligand 3), is a key chemokine involved in immune responses, particularly in the recruitment and activation of leukocytes during inflammation and infection. Research into CCL3 has expanded due to its significant role in various pathological conditions, including autoimmune diseases, viral infections, and cancer. The recombinant form of MIP-1 alpha is produced through genetic engineering techniques, which facilitate the study of its functions and potential therapeutic applications. Studies have shown that CCL3 influences the migration of T cells and monocytes to inflammatory sites, modulating the immune response. Moreover, its expression is often upregulated in diseases where the immune system is dysregulated. Understanding the signaling pathways and biological activities of recombinant CCL3 can provide valuable insights into its potential as a biomarker for disease progression and as a target for therapeutic intervention. Current research explores its therapeutic implications in enhancing immune response against tumors and addressing inflammatory diseases, making recombinant MIP-1 alpha a pivotal molecule in immunological studies.
